Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Precision Health Database


Genomics & Health Impact Scan Database|Search|PHGKB

Last data update: Mar 27, 2023. (Total: 58931 Documents since 2012)
   dataset      
Filtered By:

Previous    

Records 1 - 30 (of 137 Records)

Next

Query Trace:
Can Opioid-Free Anaesthesia Be Personalised? A Narrative Review
J Goff et al, J Per Med, March 10, 2023
A review of the genomics of neonatal abstinence syndrome.
Elizabeth Yen et al. Frontiers in genetics 2023 141140400
Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center.
Laura B Ramsey et al. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2023
Establishing a Longitudinal Opioid Pharmacogenomic Registry for Cancer Patients: Feasibility and Acceptability.
Philip Jennifer et al. Journal of palliative medicine 2022
Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative.
Kusic Dara et al. Pharmaceutics 2022 14(9)
Detection of relevant pharmacogenetic information through exome sequencing in oncology.
Verdez Simon et al. Pharmacogenomics 2022
The Role of Pharmacogenomics in Opioid Prescribing.
Wong Aaron K et al. Current treatment options in oncology 2022
Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci.
Deak Joseph D et al. Molecular psychiatry 2022
Implementing a Pragmatic Clinical Trial to Tailor Opioids for Acute Pain on behalf of the IGNITE ADOPT PGx Investigators.
Cavallari Larisa H et al. Clinical and translational science 2022
Pharmacogenetics: A Precision Medicine Approach to Combatting the Opioid Epidemic.
Smith D Max et al. Journal of the American College of Clinical Pharmacy : JACCP 2022 5(2) 239-250
The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review.
Yalçin Nadir et al. Pharmacogenomics and personalized medicine 2022 15675-696
From saliva to SNP: non-invasive, point-of-care genotyping for precision medicine applications using recombinase polymerase amplification and giant magnetoresistive nanosensors.
de Olazarra Ana Sofia et al. Lab on a chip 2022
Associations between the C3orf20 rs12496846 Polymorphism and Both Postoperative Analgesia after Orthognathic and Abdominal Surgeries and C3orf20 Gene Expression in the Brain.
Nishizawa Daisuke et al. Pharmaceutics 2022 14(4)
Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs.
Chanfreau-Coffinier Catherine et al. Pain 2022
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
Blum Kenneth et al. Psychology research and behavior management 2021 142115-2134
Profile of Medicaid enrollees with sickle cell disease: A high need, high cost population.
Grady April et al. PloS one 2021 16(10) e0257796
Ancestry may confound genetic machine learning: Candidate-gene prediction of opioid use disorder as an example.
Hatoum Alexander S et al. Drug and alcohol dependence 2021 229(Pt B) 109115
Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.
Castaldelli-Maia João M et al. Biomolecules 2021 11(10)
Cost-utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder.
Mallow Peter J et al. Journal of comparative effectiveness research 2021
Engaging pharmacogenomics in pain management and opioid selection.
Bright David R et al. Pharmacogenomics 2021
Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests
G Zhu et al, Pharmacogenomics Journal, September 2021
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid Treated Oncology Patients.
Reizine Natalie et al. The oncologist 2021
Clinical Performance of a Gene-Based Machine Learning Classifier in Assessing Risk of Developing OUD in Subjects Taking Oral Opioids: A Prospective Observational Study.
Donaldson Keri et al. Annals of clinical and laboratory science 2021 51(4) 451-460
On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications.
Nieto Steven J et al. Expert review of precision medicine and drug development 2020 5(1) 43-54
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)
M Matic et al, The Pharmacogenomics Journal, July 15, 2021
Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
Leleu Henri et al. PloS one 2021 16(7) e0253986
High-throughput framework for genetic analyses of adverse drug reactions using electronic health records.
Zheng Neil S et al. PLoS genetics 2021 17(6) e1009593
Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease
AL Elchynsky et al, The PGx journal, June 3, 2021
Pharmacogenomics in Pain Management: A Review of Relevant Gene-Drug Associations and Clinical Considerations.
Brandl Emily et al. The Annals of pharmacotherapy 2021 10600280211003875
High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.
Moran Mark et al. Molecular neurobiology 2021
TOP